MOUD Buprenorphine Subli denied as non-formulary by Centene?

Mirrors state Medicaid PDLs. Most state Medicaid programs (post-2023 X-waiver removal) allow PCP prescribing without specialist gatekeeping.

MATA Act 2022 / DATA 2000 X-waiver removal — any DEA-registered prescriber may prescribe buprenorphine. ASAM NPG OUD 2020 first-line. SAMHSA TIP 63 supports doses >24 mg for fentanyl-era patients. EPSDT for under-21.

## Why Centene Issued This Denial

Centene's "non-formulary" denial means the specific sublingual buprenorphine product prescribed is not on Centene's covered drug list for the patient's plan tier, or it is on the formulary but at a tier that was not authorized. This is common when a brand-name product is prescribed and a generic equivalent is on formulary, or when a specific film vs. tablet formulation differs from the listed formulary product.

For MOUD specifically, a non-formulary denial is subject to additional scrutiny: federal MHPAEA parity rules and, for Medicaid-managed-care plans (which many Centene subsidiaries administer), federal Medicaid requirements around access to substance use disorder treatment both create grounds to challenge formulary restrictions that effectively block access to evidence-based MOUD.

## Why This Denial Is Appealable

Non-formulary denials are overturned via two routes: (1) a formulary exception, where the prescriber documents that the non-formulary product is medically necessary because the formulary alternative is clinically inappropriate for this patient; or (2) a step-edit/tier exception showing that switching to the formulary product poses a clinical risk. Both routes require prescriber documentation.

## Federal Appeal Framework

• Internal appeal / formulary exception (Level 1): File within the deadline in the denial letter. Centene must respond within 30 days (standard) or 72 hours (expedited).
• External review (ACA §2719 / ERISA §503): Available after exhausting internal appeal — generally within four months of the final internal denial. An IRO assesses whether the formulary restriction, as applied, meets Centene's own criteria.
• Medicaid fair hearing: If the plan is a Centene Medicaid product, the member also has the right to a state Medicaid fair hearing, which runs on a separate track and can be faster.

## Concrete Appeal Steps

1. Obtain Centene's formulary and identify what buprenorphine MOUD products are covered and at which tier. 2. Determine whether the prescribed product differs from a covered formulary alternative — and if so, why. 3. Have the prescriber submit a formulary exception request documenting the clinical reason the non-formulary product is medically necessary (e.g., patient has previously failed or cannot tolerate the formulary alternative, or specific formulation characteristics are clinically required). 4. If the plan is a Medicaid product, consider filing a parallel state fair hearing request. 5. Escalate to external review if the internal exception is denied.

## Documentation to Gather

• Centene's current formulary showing the non-formulary status of the prescribed product
• Prescriber's formulary exception letter explaining why the formulary alternative is not clinically appropriate
• Chart documentation of any prior experience with the formulary alternative (e.g., inadequate response, intolerance)
• Diagnosis confirmation and treatment history
• FDA prescribing label for both the prescribed product and the formulary alternative (to support clinical distinction)

## Criteria-Mapping Structure

| Centene Formulary Exception Criterion | Supporting Evidence | |---|---| | Formulary alternative tried and failed/not tolerated | Chart notes documenting prior experience | | Formulary alternative contraindicated or clinically inappropriate | Prescriber letter with clinical rationale | | Non-formulary product medically necessary for this patient | Prescriber letter + chart documentation |